Abstract

doi:10.1136/gut.2010.226761 Emad El-Omar, Severine Vermeire and Alexander Gerbes, Editor and Deputy Editors as key mediators of this protection in during IFX maintenance is the preferred Bacterial DNA motifs and experimental colitis. See page 1347. treatment option, although risk/benefit protection against experimental profile needs to be carefully assessed. See page 1363. colitis The gut microbiota is critical for gut Co-treatment with homeostasis but also in the initiation immunomodulators in IBD Lung metastases and colorectal and perpetuation of chronic intestinal inflammation. The immunosuppressive patients on Infliximab cancer properties of bacterial DNA are the The lung is known to be the most maintenance therapy Oligodeoxynucleotides (ODN) containing common extra-abdominal site of meta- The anti-TNF antibody Infliximab (IFX) cytosineguanosine (CpG) sequence motifs. stases from CRC. However, the real is a very efficacious therapy for patients Prophylactic treatment with CpG-ODN frequency for both synchronous and with Crohn’s disease (CD) and ulcerative prevents intestinal inflammation but the metachronous lung metastases is not colitis (UC). The SONIC study showed underlying mechanisms are unknown. In known. Mitry et al studied all cases of that in anti-TNF and immunomodulator this study, the authors co-incubated total lung metastases from colorectal cancer (IMM)-naïve patients, combination therapy splenic cells or purified